Journal of Korean Dental Science

Korean Academy of Dental Science (대한치의학회)
권호 표지
DOI QR코드

DOI QR Code

Parathyroid Hormone, Can Be a New Therapy to Overcome the Bisphosphonate Related Osteonecrosis of Jaw?

  • Pyo, Sung-Woon (Department of Oral and Maxillofacial Surgery, The Catholic University of Korea Bucheon St. Mary's Hospital)
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther. 2005; 5: 817-32. https://doi.org/10.1517/14712598.5.6.817
  2. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol. 2007; 5: 475-82.
  3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  4. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2-12. https://doi.org/10.1016/S0278-2391(08)01667-4
  5. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, Nakayama T, Bessho K. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012; 41:1397-403. https://doi.org/10.1016/j.ijom.2012.06.020
  6. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144:753-61. https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  7. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993; 14: 690-709.
  8. Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M, Hock JM. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone. 2003; 33: 372-9. https://doi.org/10.1016/S8756-3282(03)00202-3
  9. Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab. 2004; 15: 60-5. https://doi.org/10.1016/j.tem.2004.01.006
  10. Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck. 2011; 33: 1366-71. https://doi.org/10.1002/hed.21380
  11. Kwon YD, Lee DW, Choi BJ, Lee JW, Kim DY. Shortterm teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int. 2012; 23: 2721-5. https://doi.org/10.1007/s00198-011-1882-9
  12. Narvaez J, Narvaez JA, Gomez-Vaquero C, Nolla JM. Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw. Osteoporos Int. 2013; 24: 731-3. https://doi.org/10.1007/s00198-012-1918-9